Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Stomach Neoplasms 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Endometrial Neoplasms 1ER+ HER2- Advanced Breast Cancer 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 26Paclitaxel 22Oxaliplatin 20Nivolumab 16Docetaxel 16Capecitabine 16Cisplatin 15Fluorouracil 11Cyclophosphamide 11fludarabine 10S 1 (combination) 10Trastuzumab 9Irinotecan 9Carboplatin 8Leucovorin 7tislelizumab 6aldesleukin 5Ramucirumab 5Interleukin-2 5Gemcitabine 5Drug Therapy 5Bevacizumab 5sintilimab 4fludarabine phosphate 4apatinib 4Radiotherapy 4Everolimus 4regorafenib 3olaparib 3durvalumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Stomach Neoplasms × AZD9833 × Clear all
NCT04644068 2026-02-19

PETRA

AstraZeneca

Phase 1/2 Active not recruiting
702 enrolled
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡